Yes that is important too, thus my comments around an assessment of the commercial opportunity being work still to come. However biotech companies in phase 2 are essentially options and it is instructive to see how the market is valuing comparable options. If you knew nothing else this would still be helpful information.
FTT relative valuation suggests fair value of around 20c, page-3
Add DLM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| DLM (ASX) Chart |
Day chart unavailable